Animal research are serving to to develop a possible new therapy for Parkinson’s illness, in response to analysis

June 21, 2022

Doris Dude and Allison J. Bennett

Parkinson’s illness (CP) is a recognized neurodegenerative illness that impacts greater than 10 million individuals worldwide. It’s the second most typical neurodegenerative illness after Alzheimer’s illness. CP is related to well-known motor signs resembling tremor, sluggish motion and an elevated danger of falls, in addition to a wide range of non-motor signs, together with temper, sleep issues and constipation. Medicines and surgical procedure permit some management over the signs, however aren’t healing, and illness development and cell dying proceed. The chance of growing BP will increase with growing older. Nonetheless, a minority of minor circumstances are associated to genetic predisposition. One of many linked genes is the LRRK2 gene. LRRK2 overload impacts the effectivity of the cell waste administration system, particularly undesirable or improperly produced proteins, resulting in a rise and accumulation of poisonous by-products, which might result in accelerated cell dying.

Parkinson’s illness is not only an aged individual’s illness: the hidden facet of the illness. Verbeeldingskr8 aka Sparks [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)

Discovery and development of potential new treatment

A new class of drugs, called DNL201 or DNL151, was recently developed that appears to have the ability to reduce the toxic accumulation by modulating the action of LRRK2.  While these DNL drugs are not expected to reverse the course of PD, it is hoped that, by reducing the cells’ exposure to their own toxic products, the cells will not suffer early and accelerated death.  If this happens it would  significantly slow down the progression of the disease and improve patients’ prognosis and lives.   

Structure of protein LRRK2. Based on PyMOL rendering of PDB 2ZEJ.   Source: https://commons.wikimedia.org/wiki/File:Protein_LRRK2_PDB_2ZEJ.png

Animal studies and preclinical results

The new drugs have been tested in rats and monkeys to assess safety. The animal tests are necessary to determine potential unwanted and unanticipated side effects of decreasing LRRK2 levels. From these animal studies, doses of DNL that could reduce toxic byproducts in the brain while maintaining adequate LRRK2 levels in  lungs and kidneys were determined. The results of the testing then led to early clinical trials aimed at confirming safety  in healthy volunteers who served as control participants and a few PD patients. Both groups took the drugs for as much as a month. Longer exposure to the drug is of course needed both in  animals and humans to replicate these safety findings but also to start evaluating efficacy and determine whether DNL will fulfill the promises and hopes the preclinical studies have raised. 

What’s next?

While the results of these early trials look promising, many further studies need to be conducted in both humans and non humans to confirm long term mechanism of action, long term safety  and furthermore, efficacy. The role of mice, rats and even non human primates engineered with the same LRRK2 abnormalities as the PD patients will be crucial to evaluate the efficacy of the drug in a timely fashion, a feat that will be difficult to achieve solely in the small human LRRK2-identified population.  Furthermore, other models of the disease (i.e. non-LRRK2 induced) in mice, rats, primates or other species like fruit flies can also be instrumental in investigating if improving “garbage disposal” in cells without an obvious LRRK2 deficit may also contribute to slowing disease progression by improving cell metabolism and survival. 

This research demonstrates the vital role of animal research in understanding the molecular mechanisms underlying complex diseases like PD. That critical  information is needed as the foundation for developing new treatments. The goal? Improved quality of life in those affected by a devastating degenerative disease, including one of the most vulnerable communities—the elderly.

Read more at:  https://www.science.org/content/article/experimental-drug-targets-early-stages-parkinson-s

Leave a Comment

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.